Atomoxetine hydrochloride Usage And Synthesis |
Introduction |
Atomoxetine hydrochloride is the hydrochloride form of the nervous system drug atomoxetine, which is an adrenergic transmitter reuptake inhibitor
used to treat attention deficit and hyperactivity disorder. Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) with a structure
similar to fluoxetine. The drug is the first stimulant drug approved by Chemicalbook for the treatment of attention deficit
hyperactivity disorder (ADHD). In clinical trials, it was not found to cause the typical reactions common to other stimulant drugs or drugs
that can cause euphoria.Randomized, placebo-controlled trials in children and adults have confirmed that the product is effective in treating ADHD. |
|
[Developer] Eli Lilly, Inc., USA |
[Trade name] Strattera |
[Other name] LY139603 |
[Country and year of launch] USA, 2003 |
Properties |
Atomoxetine hydrochloride is a white or off-white solid, soluble in water (27.8 mg/ml). |
Pharmacological action |
The exact mechanism of atomoxetine hydrochloride in treating ADHD in children is still unclear.
It is currently believed that the therapeutic effect of this product is related to other selective inhibition of the reuptake effect of
presynaptic amine pumps on norepinephrine, which can enhance the reversal effect of norepinephrine, thereby improving the symptoms of ADHD in
children and indirectly promoting the completion of cognition and concentration of attention. |
Indications |
Atomoxetine hydrochloride is suitable for the treatment of ADHD in children and adolescents. |
Synthesis method |
Using 3-methylamino-1-phenylpropanol as the starting material, it reacts with 2-fluorotoluene to form an ether, is split with L-(+)-mandelic acid,
and finally is salted with dry hydrogen chloride. Chemicalbook undergoes three steps of reaction to prepare atomoxetine hydrochloride.
This synthetic route is simple, has a high relative yield, and is suitable for the preparation process
of industrial production to synthesize the target compound atomoxetine hydrochloride. |
Side effects |
Atomoxetine has few side effects, most of which occur in the early stages of treatment, mainly manifested as decreased appetite,
insomnia, and fatigue. Possible weight loss will slowly return to normal as treatment progresses. Some patients may experience mild increases
in blood pressure and heart rate, but no cardiovascular side effects were found in 169 ADHD patients who were followed up after taking atomoxetine for one year. |
Precautions |
1. Use with caution in patients with hypertension, heart disease, hypotension or hypotension tendency, renal insufficiency,
jaundice, liver disease, urinary retention or bladder dysfunction.
2. There is still a lack of clinical research data on the use of the drug in children under 6 years old, and some children may experience
weight loss in the early stage of treatment.
3. There is still a lack of clinical research data on the use of the drug in the elderly.
4. Animal experiments have shown that large doses of this product can have teratogenic effects on the fetus, and pregnant women should use
it with caution. The FDA has classified this drug as Class C for pregnancy safety.
5. Use with caution in breastfeeding women.
6. Patients who are taking or have taken monoamine oxidase inhibitors such as phenelzine and phenylcypromine
within 14 days are prohibited from using this drug. |
